

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAY 2009 HIGHEST RN 1144177-22-9
 DICTIONARY FILE UPDATES: 7 MAY 2009 HIGHEST RN 1144177-22-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> s 165537-73-5/rn
L1          1 165537-73-5/RN
```

```
=> d
```

```
L1  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN  165537-73-5  REGISTRY
ED  Entered STN: 01 Aug 1995
CN  1-Naphthalene propanoic acid, 6-[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-
    tetrahydro-2-methyl- (CA INDEX NAME)
DR  309298-16-6
MF  C20 H22 Cl N O4 S
CI  COM
SR  CA
LC  STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, CHEMCATS, EMBASE,
    IMSPATENTS, IMSRESEARCH, PHAR, PROUSDDR, TOXCENTER, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1907 TO DATE)
 15 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/923,271

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	2.53	3.25

FILE 'CAPLUS' ENTERED AT 17:00:57 ON 08 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 May 2009 VOL 150 ISS 20
FILE LAST UPDATED: 7 May 2009 (20090507/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CPlus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

=> s 165537-73-5 and clopidogrel
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L3 15 L2

L4 2634 CLOPIDOGREL
3 L3 AND CLOPIDOGREL

=> d l-3 ibib abs hitstr

TOh

08/05/2009


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 20081251839 CAPLUS
 DOCUMENT NUMBER: 149:455387
 TITLE: Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor for treatment of thrombotic disease
 INVENTOR(S): Sinha, Uma; Hollenbach, Stanley J.; Andre, Patrick
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 24pp.
 CODEN: USXKC0
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080254036	A1	20081016	US 2008-101644	20080411
WO 2008127682	A2	20081023	WO 2008-US4760	20080411
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2007-911852P P 20070413

AB The present invention is directed to methods of using combination therapies containing [2-(4-[1(dimethylamino)iminomethyl]phenyl)carbonylamino]-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide (Compound A) for the treatment of thrombotic disease(s) and pharmaceutical compns. thereof. Thus, combination of Compound A and aspirin in thrombin generation assay in platelet rich plasma (PRP) was tested: human platelet poor plasma (PPP) or platelet rich plasma (PRP) was prepared from blood of healthy donors; for thrombin generation in 100 μ L reaction mixture, 75 μ L PRP was first mixed with CaCl₂, convulxin, and Z-Gly-Gly-Arg-aminomethylcoumarin, followed by adding tissue factor to initiate the generation of thrombin; inhibitors were preincubated with plasma for 20 min at room temperature before adding CaCl₂ and convulxin. For 15.625 nM concentration of Compound A in combination with aspirin, the inhibition was 26.9%, compared to 5.1% without aspirin.

IT 165537-73-5
 RL: TEM (Technical or engineered material use); USES (Uses)
 (combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor)
 RN 165537-73-5 CAPLUS
 CN 1-Naphthalene propanoic acid, 6-[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005301861 CAPLUS
 DOCUMENT NUMBER: 142:329857
 TITLE: Synergistic combination of an anti-atherothrombotic agent and a platelet aggregation inhibitor
 INVENTOR(S): Cloarec, Blanchard Laure; Corda, Stefano; Lerond, Laurence
 PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
 SOURCE: Fr. Demande, 10 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2860436	A1	20050408	FR 2003-11595	20031003
FR 2860436	B1	20060120		
AU 2004277734	A1	20050414	AU 2004-277734	20041001
AU 2004277734	B2	20070524		
CA 2540062	A1	20050414	CA 2004-2540062	20041001
WO 2005032533	A1	20050414	WO 2004-FR2489	20041001
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1677779	A1	20060712	EP 2004-791453	20041001
EP 1677779	B1	20080924		
R: AI, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1859902	A	20061108	CN 2004-80028356	20041001
CN 100453075	C	20090121		
BR 2004015043	A	20061212	BR 2004-15043	20041001
JP 2007507475	T	20070329	JP 2006-530412	20041001
AT 409033	T	20081015	AT 2004-791453	20041001
NZ 545988	A	20081128	NZ 2004-545988	20041001
ES 2314457	T3	20090316	ES 2004-791453	20041001
IN 2006DN01446	A	20070803	IN 2006-DN1446	20060317

US 20070054934	A1	20070308	US 2006-574119	20060330
MX 200603713	A	20060614	MX 2006-3713	20060403
KR 2006061399	A	20060607	KR 2006-708071	20060426
KR 782246	B1	20071205		


PRIORITY APPLN. INFO.: FR 2003-11595 A 20031003
WO 2004-FR2489 W 20041001

AB A new synergistic combination of an anti-atherothrombotic agent and a platelet aggregation inhibitor is claimed. Combination of 75 mg clopidogrel and 10 mg of 6-[(4-chlorophenyl)sulfonyl]amino-5,6,7,8-tetrahydro-2-methyl-1-naphthalene propanoic acid administered orally to volunteers for 3 days decreased the platelet aggregation by 62% as compared to 11% for clopidogrel alone.

IT 165537-73-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic combination of anti-atherothrombotic agent and platelet aggregation inhibitor)

RN 165537-73-5 CAPLUS

CN 1-Naphthalene propanoic acid, 6-[(4-chlorophenyl)sulfonyl]amino-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:405522 CAPLUS

DOCUMENT NUMBER: 1411:374569

TITLE: Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist

AUTHOR(S): Osende, J. I.; Shimbo, D.; Fuster, V.; Dubar, M.; Badimon, J. J.

CORPORATE SOURCE: Cardiovascular Biology Research Laboratory and Cardiovascular Institute, Mount Sinai School of Medicine, New York City, NY, USA

SOURCE: Journal of Thrombosis and Haemostasis (2004), 2(3), 492-498

PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Platelet activation and thrombus formation play a critical role in the onset of acute coronary syndromes. Thromboxane A2 (Tx_A2) is among the different chemical modulators released by activated platelets. Tx_A2 is considered one of the most powerful agonists for platelet activation. In addition, Tx_A2 exerts a vasoconstrictor effect by serving as an agonist of the thromboxane receptor (TP) on the vascular smooth muscle cell membranes.

The putative effect of TxA₂ on thrombosis is demonstrated by the clin. effectiveness of acetylsalicylic acid (ASA) in the prevention of acute coronary syndromes. Among the clin. used antiplatelet agents, clopidogrel has shown to be slightly more effective than ASA in the prevention of atherothrombotic events in patients with peripheral arterial disease, and is one of the most widely used after aspirin. The aims of the study were to study the antithrombotic effects of escalating doses of the TP-receptor antagonist, S 18886 and to compare its effects with those achieved by the administration of ASA (5 mg kg⁻¹ day⁻¹), and clopidogrel (3 mg kg⁻¹ day⁻¹). The study was undertaken at high and low shear rate conditions using the Badimon perfusion chamber in a porcine model. Antithrombotic effects were assessed as changes on platelet and fibrinogen deposition. The doses of 30 and 100 µg kg⁻¹ day⁻¹ were selected based on a previous platelet aggregation study. S 18886 shows a dose-dependent antithrombotic response. The dose of S-100 develops similar antithrombotic effects to those of clopidogrel and superior to those of aspirin. The antithrombotic effects were statistically significant at both studied shear rate conditions. Therefore, the orally active TP-receptor antagonist, S 18886, appears to be a new and effective agent to prevent atherothrombotic complications.


IT 165537-73-5, S 18886

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TP-receptor antagonist S 18886 at 100µg/kg/day exerted dose-dependent antithrombotic effect similar to clopidogrel but superior to ASA at high, low shear rates as evident by inhibition of platelet and fibrinogen deposition in pig model)

RN 165537-73-5 CAPLUS

CN 1-Naphthalene propanoic acid, 6-[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



REFERENCE COUNT:

33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT